"Working at Genentech allows one the opportunity to push the boundaries of science, and then see the fruits of discovery be directed toward the benefit of patients."
I joined Genentech as a Scientist in 2015, part of a new Quantitative & Systems Pharmacology group. Our aim is to build computational models of disease at the cellular level, and use these models to explore, via simulations, how to better design, develop, and use new medicines to treat disease. We thus borrow approaches from engineering, mathematics, and computer science to address pressing medical problems.
My background is in chemical engineering – I have a PhD from the University of Toronto, and before moving to California did a post-doc at MIT, and worked in the Boston-area biotech industry. Working at Genentech allows me the opportunity to push the boundaries of science, and then see the fruits of discovery be directed toward the benefit of patients.
CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):235-49.
PLoS Comput Biol. 2016 Apr 1;12(4):e1004827.
I develop computational models to support oncology drug development programs. These range from biochemically detailed models of cancer cell signaling, to more empirical models of drug pharmacology and tumor growth, to data-driven genomic analyses, depending on the questions at hand and data available. I work on both small molecules and antibody-based drugs, and focus on problems spanning basic research, to early molecule design, clinical strategy, and biomarker development.